UK - Schemes should boost their exposure to the pharmaceuticals sector as it will be one of the few growth areas in 2003, Newton Investment Management claims.
The sector was marked down during 2002 due to concerns in the US about enforced price changes and fears about the ability of firms to create more “blockbuster” drugs.
To continue reading this article...
Join Professional Pensions
- Unlimited access to real-time news, analysis and opinion from the industry
- Receive our in-depth monthly magazine in either print or digital format
- Access our Sustainable Investment Hub covering news and opinion from thought leaders in the ESG space
- Receive important and breaking news stories selected by the Editors in our daily newsletter
- Hear from industry experts and other forward-thinking leaders
- Receive a monthly members-only newsletter with exclusive opinion pieces from leading industry experts and a feature from the magazine in advance of its release date